Home > Insider Trading > Filing (0001725160-25-000041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	Pharmaceutical Preparations (2834)	823607803

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1777413	Mark Lackner	C/O Zentalis Pharmaceuticals, Inc. 10275 Science Center Drive, Suite 200 San Diego CA 92121	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-02-03	335,907	$0.00	527,224	No	4	A	Direct
Common Stock	Disposition	2025-02-03	14,368	$1.71	512,856	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-02-03	124,714	$0.00	124,714	$1.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
124,714		2035-02-02	No	4	A	Direct

Footnotes

Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.